Table 1.
Physiologic Parameter | PET | CT | MRI |
---|---|---|---|
Hemorrhage | Hyperdense | T2 * hypo-intensity, 130 SWI, 130 APT 131 | |
Site of occlusion | CTA | MRA | |
destined for infarction (Neuronal death) | 11C-FMZ 18F-BCPP-EF | Hypodense | T2 hyper-intensity |
CBV | 15O2 | CTP | DSC, VASO (mainly GM) 132 |
CBVa | iVASO (mainly GM) 133 | ||
CBF | 15O2 | XeCT/CTP | DSC, ASL (mainly GM) 134 |
MTT | 15O2 | CTP | DSC |
CMRO2 | 15O2 | QSM, indirectly by 13C MRS, MRI | |
OEF increase | 15O2 | QSM, T2 and T2 * mild hypo-intensity | |
CMRGlc | 18FDG | 13C MRS | |
Hypoxia | 18F-MISO | BOLD (T2, T2 * ) | |
Lactate | 1H MRS, 13C MRS | ||
pH | 11CO2, 11C-DMO | 31P MRS, CEST/APT MRI | |
PCr/Cr | 31P MRS, CEST MRI128 | ||
ATP | 31P MRS | ||
Na | 23Na MRI | ||
ADC | DWI, DTI |
MRI methods possible on standard clinical scanners are in BOLD.
Most citations are in the text; only references for clinically accessible methods not mentioned in the text are added to the table.
FMZ: flumazenil; 18F-BCPP-EF: 2-tert-butyl-4-chloro-5-{6-[2-(2-(18)F-fluoroethoxy)-ethoxy]-pyridin-3-ylmethoxy}-2H-pyridazin-3-one; FDG: Fluorodeoxyglucose; MISO: misonidazole; DMO: dimethyloxazolidinedione; CTA: CT angiography; CTP: CT perfusion; SWI: Susceptibility-weighted imaging; CEST: Chemical exchange saturation transfer; APT: Amide proton transfer; MRA: Magnetic resonance angiography; DSC: Dynamic susceptibility contrast; VASO: Vascular space occupancy; iVASO: inflow VASO; ASL: Arterial spin labeling; QSM: Quantitative susceptibility mapping; MRS: MR spectroscopy; DWI: Diffusion weighted imaging; DTI: Diffusion tensor imaging.